Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 4.6% - Still a Buy?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) were up 4.6% on Friday . The company traded as high as $6.20 and last traded at $6.22. Approximately 4,144,273 shares changed hands during mid-day trading, a decline of 60% from the average daily volume of 10,307,810 shares. The stock had previously closed at $5.94.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on RXRX shares. Cowen reiterated a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. KeyCorp decreased their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 8th. Needham & Company LLC restated a "buy" rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Finally, Leerink Partners lowered their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research report on Friday, February 28th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $8.25.

Recursion Pharmaceuticals Price Performance

The stock has a market cap of $2.55 billion, a P/E ratio of -4.15 and a beta of 0.85. The business has a 50-day simple moving average of $7.57 and a 200 day simple moving average of $7.03. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04.

Remove Ads

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its earnings results on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The company had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business's revenue was down 57.8% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.42) earnings per share. On average, analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in shares of Recursion Pharmaceuticals by 40.1% in the 4th quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock worth $229,908,000 after purchasing an additional 9,737,196 shares in the last quarter. Softbank Group CORP. bought a new stake in shares of Recursion Pharmaceuticals during the fourth quarter worth about $99,152,000. State Street Corp raised its holdings in shares of Recursion Pharmaceuticals by 47.1% in the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company's stock worth $84,815,000 after acquiring an additional 4,120,685 shares during the last quarter. Novo Holdings A S bought a new position in Recursion Pharmaceuticals in the 4th quarter valued at about $68,375,000. Finally, FMR LLC boosted its stake in Recursion Pharmaceuticals by 2.1% during the 3rd quarter. FMR LLC now owns 8,363,530 shares of the company's stock valued at $55,116,000 after purchasing an additional 170,810 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company's stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.